09:13 AM EST - BioVaxys Technology Corp : Announced today that Millipore-Sigma, the contract manufacturer for its preclinical viral vaccine program, has completed the bioproduction and batch release endotoxin screening of BVX-1021, the Company's vaccine for SARS-CoV, which is being used in the collaboration with The Ohio State University to develop a pan-sarbecovirus vaccine. The next step is measuring neutralizing antibody development to sarbecoviruses following immunization of study animals with BVX-1021, followed by administration of a SARS-CoV-2 vaccine---in this case with BVX-0320, the Company's Covid-19 vaccine candidate. BioVaxys Technology Corp
shares C.BIOV are trading unchanged at $0.11.
